Elisa Camela

1.3k total citations
41 papers, 793 citations indexed

About

Elisa Camela is a scholar working on Dermatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Elisa Camela has authored 41 papers receiving a total of 793 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Dermatology, 27 papers in Immunology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Elisa Camela's work include Psoriasis: Treatment and Pathogenesis (27 papers), Dermatology and Skin Diseases (20 papers) and Autoimmune Bullous Skin Diseases (6 papers). Elisa Camela is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (27 papers), Dermatology and Skin Diseases (20 papers) and Autoimmune Bullous Skin Diseases (6 papers). Elisa Camela collaborates with scholars based in Italy, Mexico and Romania. Elisa Camela's co-authors include Matteo Megna, Gabriella Fabbrocini, Angelo Ruggiero, Luca Potestio, Eleonora Cinelli, Claudio Marasca, Fabrizio Martora, Teresa Battista, Sabatino Pallotta and Luigi Fornaro and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American Academy of Dermatology and Journal of Clinical Medicine.

In The Last Decade

Elisa Camela

37 papers receiving 783 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elisa Camela Italy 18 639 488 145 144 70 41 793
Michael Bukhalo United States 10 518 0.8× 361 0.7× 110 0.8× 88 0.6× 41 0.6× 18 668
Paolo Dapavo Italy 19 588 0.9× 532 1.1× 179 1.2× 162 1.1× 50 0.7× 82 938
T.N. Dam Denmark 14 753 1.2× 462 0.9× 126 0.9× 119 0.8× 123 1.8× 21 1.0k
Ziqian Geng United States 9 706 1.1× 552 1.1× 135 0.9× 108 0.8× 55 0.8× 14 1.1k
Nikolai Loft Denmark 18 559 0.9× 516 1.1× 182 1.3× 76 0.5× 61 0.9× 51 1.0k
Darío Kivelevitch United States 13 490 0.8× 254 0.5× 92 0.6× 112 0.8× 27 0.4× 22 643
M. Milutinovic Switzerland 7 965 1.5× 637 1.3× 139 1.0× 217 1.5× 46 0.7× 12 1.0k
Eleonora Cinelli Italy 15 363 0.6× 328 0.7× 103 0.7× 60 0.4× 35 0.5× 36 540
Arianna Zangrilli Italy 13 432 0.7× 277 0.6× 70 0.5× 75 0.5× 38 0.5× 38 547
D. Toth Canada 5 555 0.9× 565 1.2× 193 1.3× 96 0.7× 24 0.3× 6 800

Countries citing papers authored by Elisa Camela

Since Specialization
Citations

This map shows the geographic impact of Elisa Camela's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa Camela with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa Camela more than expected).

Fields of papers citing papers by Elisa Camela

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisa Camela. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa Camela. The network helps show where Elisa Camela may publish in the future.

Co-authorship network of co-authors of Elisa Camela

This figure shows the co-authorship network connecting the top 25 collaborators of Elisa Camela. A scholar is included among the top collaborators of Elisa Camela based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa Camela. Elisa Camela is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Camela, Elisa, Anna Rita Giampetruzzi, Ornella De Pità, Sabatino Pallotta, & Filomena Russo. (2024). Dupilumab in real-life settings: a review of adverse events and their pathogenesis. Expert Opinion on Drug Safety. 23(4). 439–447. 10 indexed citations
2.
3.
Megna, Matteo, Elisa Camela, Angelo Ruggiero, et al.. (2023). Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?. Clinical Cosmetic and Investigational Dermatology. Volume 16. 1677–1690. 20 indexed citations
4.
Potestio, Luca, Teresa Battista, Sara Cacciapuoti, et al.. (2023). New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge. Biomedicines. 11(8). 2191–2191. 8 indexed citations
5.
Potestio, Luca, Elisa Camela, Sara Cacciapuoti, et al.. (2023). Biologics for the Management of Erythrodermic Psoriasis: An Updated Review. Clinical Cosmetic and Investigational Dermatology. Volume 16. 2045–2059. 12 indexed citations
6.
Potestio, Luca, Elisa Camela, Sara Cacciapuoti, et al.. (2023). Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation. Expert Opinion on Drug Safety. 22(11). 1003–1010. 4 indexed citations
7.
Camela, Elisa, Konstantinos Lallas, Chryssoula Papageorgiou, et al.. (2023). Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma Subtypes. Medicina. 59(2). 349–349. 11 indexed citations
8.
Papageorgiou, Chryssoula, et al.. (2023). Acral Melanocytic Nevi in a High-Risk Population: Prevalence, Clinical Characteristics and Dermatoscopic Patterns. Dermatology. 239(5). 753–759. 1 indexed citations
9.
Megna, Matteo, Elisa Camela, Teresa Battista, et al.. (2023). Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opinion on Drug Safety. 22(1). 43–58. 40 indexed citations
10.
Camela, Elisa, Konstantinos Lallas, Chryssoula Papageorgiou, et al.. (2023). The Natural Evolution of Nevi with Peripheral Globules. Dermatology. 239(5). 760–767.
11.
Marasca, Claudio, Maria Carmela Annunziata, Elisa Camela, et al.. (2022). Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. Journal of Clinical Medicine. 11(6). 1511–1511. 32 indexed citations
12.
Megna, Matteo, Luigi Fornaro, Luca Potestio, et al.. (2022). Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study. SHILAP Revista de lepidopterología. Volume 12. 199–204. 13 indexed citations
13.
Ocampo‐Garza, Sonia Sofìa, Jorge Ocampo‐Candiani, Elisa Camela, et al.. (2021). Nail changes as manifestation of systemic disease in COVID‐19 infection. Journal of the European Academy of Dermatology and Venereology. 35(8). e474–e475. 7 indexed citations
14.
Camela, Elisa, Sonia Sofìa Ocampo‐Garza, Eleonora Cinelli, et al.. (2021). Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. Dermatologic Therapy. 34(2). e14857–e14857. 17 indexed citations
15.
Ruggiero, Angelo, et al.. (2021). Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice. Clinical and Experimental Dermatology. 47(3). 561–567. 71 indexed citations
16.
Megna, Matteo, Eleonora Cinelli, Lucia Gallo, et al.. (2021). Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Archives of Dermatological Research. 314(6). 619–623. 39 indexed citations
17.
Megna, Matteo, Gabriella Fabbrocini, Eleonora Cinelli, Elisa Camela, & Angelo Ruggiero. (2020). Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. Journal of Dermatological Treatment. 33(2). 1074–1078. 35 indexed citations
18.
Megna, Matteo, Gabriella Fabbrocini, Elisa Camela, & Eleonora Cinelli. (2020). Apremilast efficacy and safety in elderly psoriasis patients over a 48‐week period. Journal of the European Academy of Dermatology and Venereology. 34(11). e705–e707. 13 indexed citations
19.
Megna, Matteo, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini, & Claudio Marasca. (2020). A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatologic Therapy. 33(2). e13238–e13238. 35 indexed citations
20.
Camela, Elisa, et al.. (2020). Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II. Dermatology. 237(1). 13–14. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Bukhalo Breakdown of academic impact, for papers by Paolo Dapavo Breakdown of academic impact, for papers by T.N. Dam Breakdown of academic impact, for papers by Ziqian Geng Breakdown of academic impact, for papers by Nikolai Loft Breakdown of academic impact, for papers by Darío Kivelevitch Breakdown of academic impact, for papers by M. Milutinovic Breakdown of academic impact, for papers by Eleonora Cinelli Breakdown of academic impact, for papers by Arianna Zangrilli Breakdown of academic impact, for papers by D. Toth
Rankless by CCL
2026